Back to News
Nov 3, 2025 12:00 PM

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera.

In September, Pfizer agreed to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion.

Also Read: Kimberly-Clark Stock Plunges Over 16%, Kenvue Surges 20% In Monday Premarket: What's Going On?

Last week, Metsera received an unsolicited acquisition proposal from Novo Nordisk valued at around $9 billion.

Pfizer alleges that the Novo Nordisk offer cannot qualify ...